All In Biotech

Drug Trial Radar · NCT05321082

A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)

A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of BI 1015550 Over at Least 52 Weeks in Patients With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)

Last checked: Nov 19, 2026Latest source record: Jan 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,178 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,178

Actual

Start

Nov 16, 2022

Primary completion

Dec 18, 2024

Study completion Apr 14, 2025

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Apr 11, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs). People who have a form of PF-ILD other than Idiopathic Pulmonary Fibrosis (IPF) can join the study. If they already take nintedanib, they can continue treatment throughout the study. The purpose of this study is to find out whether a medicine called BI 1015550 helps people with PF-ILD. Participants are put into 3 groups randomly, which means by chance. Participants in 2 groups take different doses of BI 1015550 as tablets twice a day. Participants in the placebo group take placebo tablets twice a day. Placebo tablets look like BI 1015550 tablets but do not contain any medicine. Participants are in the study for up to two and a half years. During the first year, they visit the study site 10 times. Afterwards, they visit the study site every 3 months. The doctors regularly test participants' lung function. The results of the lung function tests are compared between the groups. The doctors also regularly check participants' health and take note of any unwanted effects.

Conditions

  • Lung Diseases, Interstitial

Interventions

  • BI 1015550Drug

    Participants received film-coated nerandomilast tablets orally, twice daily, at doses of either 9 mg or 18 mg, in the morning and in the evening.

  • PlaceboDrug

    Participants received placebo matching 9 mg or 18 mg nerandomilast film-coated tablets orally, twice daily, in the morning and in the evening.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absolute Change From Baseline in Forced Vital Capacity (FVC) in Milliliters [mL] at Week 52Time frame: The MMRM model is a longitudinal analysis, and it incorporated FVC measurements change from baseline at Week 1, Week 2, Week 6, Week 12, Week 18, Week 26, Week 36, Week 44 and Week 52. Data presented is the FVC adjusted change from baseline at Week 52.

Locations

400 sites in 45 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • University of Arizona

    Tucson, Arizona

  • University of Southern California

    Los Angeles, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • University of California Los Angeles

    Los Angeles, California

  • University of California Davis

    Sacramento, California

  • National Jewish Health

    Denver, Colorado

  • Yale University School of Medicine

    New Haven, Connecticut

  • Christiana Hospital

    Newark, Delaware

  • St. Francis Medical Institute

    Clearwater, Florida

  • University of Florida Health Shands Hospital

    Gainesville, Florida

  • Clinical Research Specialists LLC

    Kissimmee, Florida

  • Advanced Pulmonary Research Institute

    Loxahatchee Groves, Florida

  • Destin Pulmonary Critical Care

    Santa Rosa Beach, Florida

  • Piedmont Physicians Pulmonary & Sleep Medicine of Buckhead

    Atlanta, Georgia

  • The Emory Clinic

    Atlanta, Georgia

  • Evanston Hospital Pulmonary Clinic

    Evanston, Illinois

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Tulane University Hospital and Clinic

    New Orleans, Louisiana

  • Johns Hopkins Hospital

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • St. Elizabeth's Medical Center

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Infinity Medical Research

    North Dartmouth, Massachusetts

  • University of Michigan Health System

    Ann Arbor, Michigan

  • Beaumont Health

    Royal Oak, Michigan

  • University of Minnesota

    Minneapolis, Minnesota

  • Mayo Clinic, Rochester

    Rochester, Minnesota

  • Washington University School of Medicine

    St Louis, Missouri

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Renown Regional Medical Center

    Reno, Nevada

  • Stony Brook University Medical Center

    Commack, New York

  • Lenox Hill Hospital

    New York, New York

  • Columbia University Medical Center-New York Presbyterian Hospital

    New York, New York

  • NewYork-Presbyterian/Weill Cornell Medical Center

    New York, New York

  • Duke University Medical Center

    Durham, North Carolina

  • Southeastern Research Center-Winston-Salem-61365

    Winston-Salem, North Carolina

  • University of Cincinnati

    Cincinnati, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

Showing 40 of 400 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.